[go: up one dir, main page]

YU10192A - Postupak za dobijanje derivata imidazola, triazola i tetrazola - Google Patents

Postupak za dobijanje derivata imidazola, triazola i tetrazola

Info

Publication number
YU10192A
YU10192A YU10192A YU10192A YU10192A YU 10192 A YU10192 A YU 10192A YU 10192 A YU10192 A YU 10192A YU 10192 A YU10192 A YU 10192A YU 10192 A YU10192 A YU 10192A
Authority
YU
Yugoslavia
Prior art keywords
derivatives
triazole
preparation
salts
imidasol
Prior art date
Application number
YU10192A
Other languages
English (en)
Other versions
YU48236B (sh
Inventor
R. Baker
V. Matassa
L. Street
Original Assignee
Merck Sharp And Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU10192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919102222A external-priority patent/GB9102222D0/en
Priority claimed from GB919106917A external-priority patent/GB9106917D0/en
Priority claimed from GB919113415A external-priority patent/GB9113415D0/en
Priority claimed from GB919122451A external-priority patent/GB9122451D0/en
Application filed by Merck Sharp And Dohme Limited filed Critical Merck Sharp And Dohme Limited
Priority to SI9210101A priority Critical patent/SI9210101B/sl
Priority to HR930777A priority patent/HRP930777B1/xx
Publication of YU10192A publication Critical patent/YU10192A/sh
Publication of YU48236B publication Critical patent/YU48236B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Paints Or Removers (AREA)
  • Lubricants (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Dental Preparations (AREA)

Abstract

Pronalazak se odnosi na dobijanje i na svojstva jedinjenja iz klase supstituisanih derivata imidazola, triazola i tetrazola i njihovih prihvatljivih soli, opšte formule I u kojoj isprekidan krug predstavlja nesusedne dvostruke veze u svakom položaju petočlanog prstena; V, W, X, Y i Z mogu da budu atom azota ili ugljenika, i značenja za A1, A2, E i F definisana su u patentnim zahtevima. Osim dobijanja gornjih derivata izloženo je i dobijanje njihovih soli prvenstveno oksalata, sukcinata, benzoata i hidrohlorida. Navedeni derivati i njihove prizvatljive soli imaju aktivno dejstvo na 5-hidrok-sitriptamin receptore, selektivni su agonisti takozvanih "5-HT1-ličnih" receptora.
YU10192A 1991-02-01 1992-01-30 Postupak za dobijanje derivata imidazola, triazola i tetrazola YU48236B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI9210101A SI9210101B (en) 1991-02-01 1992-01-30 Imidazole,triazole and tetrazole derivates.
HR930777A HRP930777B1 (en) 1991-02-01 1993-04-02 Imidazole, triazole and tetrazole derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919102222A GB9102222D0 (en) 1991-02-01 1991-02-01 Therapeutic agents
GB919106917A GB9106917D0 (en) 1991-04-03 1991-04-03 Therapeutic agents
GB919113415A GB9113415D0 (en) 1991-06-21 1991-06-21 Therapeutic agents
GB919122451A GB9122451D0 (en) 1991-10-23 1991-10-23 Therapeutic agents

Publications (2)

Publication Number Publication Date
YU10192A true YU10192A (sh) 1995-03-27
YU48236B YU48236B (sh) 1997-08-22

Family

ID=27450619

Family Applications (1)

Application Number Title Priority Date Filing Date
YU10192A YU48236B (sh) 1991-02-01 1992-01-30 Postupak za dobijanje derivata imidazola, triazola i tetrazola

Country Status (30)

Country Link
US (4) US5298520A (sh)
EP (2) EP0778275B1 (sh)
JP (1) JP2500280B2 (sh)
KR (1) KR100212111B1 (sh)
CN (4) CN1038681C (sh)
AT (1) ATE158582T1 (sh)
BG (1) BG62024B2 (sh)
CA (2) CA2238140C (sh)
CY (1) CY2095B1 (sh)
CZ (1) CZ283018B6 (sh)
DE (2) DE19975007I2 (sh)
DK (1) DK0497512T3 (sh)
ES (2) ES2162188T3 (sh)
FI (1) FI107154B (sh)
GR (2) GR3025026T3 (sh)
HR (1) HRP930777B1 (sh)
HU (2) HU222350B1 (sh)
IE (1) IE920342A1 (sh)
IL (1) IL100756A (sh)
LU (1) LU90338I2 (sh)
LV (1) LV12090B (sh)
MX (1) MX9200405A (sh)
NL (1) NL980019I1 (sh)
NO (2) NO180447C (sh)
NZ (1) NZ241394A (sh)
SA (1) SA94140534B1 (sh)
SG (1) SG50409A1 (sh)
SI (1) SI9210101B (sh)
SK (1) SK278998B6 (sh)
YU (1) YU48236B (sh)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219974B (hu) * 1990-06-07 2001-10-28 Astrazeneca Ab, Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
AU2363492A (en) * 1991-08-03 1993-03-02 Smithkline Beecham Plc 5-ht4 receptor antagonists
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
TW288010B (sh) * 1992-03-05 1996-10-11 Pfizer
US5510362A (en) * 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
GB9207396D0 (en) * 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
EP0635017A1 (en) 1992-04-07 1995-01-25 Pfizer Inc. Indole derivatives as 5-ht1 agonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
NZ251047A (en) * 1992-04-10 1996-09-25 Pfizer Acylaminoindole derivatives and medicaments
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208463D0 (en) * 1992-04-16 1992-06-03 Merck Sharp & Dohme Therapeutic agents
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
EP0573221B1 (en) * 1992-06-05 1998-04-29 Merck Sharp & Dohme Ltd. The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process
EP0651749A1 (en) * 1992-07-24 1995-05-10 MERCK SHARP & DOHME LTD. Imidazole, triazole and tetrazole derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
TW251284B (sh) * 1992-11-02 1995-07-11 Pfizer
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6060473A (en) * 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
US6077846A (en) * 1993-09-10 2000-06-20 Ucb, S.A. Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
GB9402011D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
GB9402016D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
US6117889A (en) * 1994-04-01 2000-09-12 University Of Virginia 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
US5552402A (en) * 1994-05-19 1996-09-03 Merck, Sharp & Dohme Ltd. Five-membered heteroaromatic compounds as 5-HT receptor agonists
WO1995032196A1 (en) * 1994-05-19 1995-11-30 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
US5567824A (en) * 1994-05-24 1996-10-22 Merck & Co., Inc. Palladium catalyzed ring closure of triazolyltryptamine
WO1996003400A1 (en) * 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
CA2195107A1 (en) * 1994-08-02 1996-02-15 Richard Alexander Jelley Azetidine, pyrrolidine and piperidine derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
US5484763A (en) * 1995-02-10 1996-01-16 American Cyanamid Company Substituted benzisoxazole and benzisothiazole herbicidal agents
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US5602168A (en) * 1995-07-10 1997-02-11 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
US6245768B1 (en) 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5656632A (en) * 1995-06-05 1997-08-12 Neurogen Corporation 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands
ATE207485T1 (de) * 1995-07-11 2001-11-15 Merck & Co Inc Ein triazolylmethyl-indol-ethylamin-bisulfat-salz
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
GB9610978D0 (en) * 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
WO1998007497A1 (de) 1996-08-19 1998-02-26 Volkswagen Aktiengesellschaft FREMDGEZÜNDETE BRENNKRAFTMASCHINE MIT EINEM NOx-ADSORBER
JP2001503668A (ja) 1996-08-19 2001-03-21 フォルクスワーゲン・アクチェンゲゼルシャフト ＮＯ▲下ｘ▼吸収体
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
PT1068198E (pt) * 1998-03-09 2003-10-31 Lundbeck & Co As H Indoles 5-heteroarilo substituidos
DE69922688T2 (de) 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
ES2292636T3 (es) * 2000-11-29 2008-03-16 Eli Lilly And Company 1-(2-m-metanosulfanomidofeniletil)-4-(m-trifluorometilfenil)piper.
US20030096379A1 (en) * 2001-03-28 2003-05-22 Kilgore James L. Method for producing tryptamine derivatives
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
DE10214228A1 (de) * 2002-03-22 2003-10-02 Bdd Group Holding Ag Zug Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel
RU2320663C2 (ru) 2002-06-21 2008-03-27 Сувен Лайф Сайенсиз Лимитед Новые арилалкилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
ATE377603T1 (de) 2002-06-21 2007-11-15 Suven Life Sciences Ltd Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
US7507835B2 (en) 2002-11-28 2009-03-24 Suven Life Sciences Ltd. N-arylsulfonyl-3-aminoalkoxyindoles
CN1720225B (zh) 2002-11-28 2011-05-18 苏文生命科学有限公司 具有5-羟色胺受体亲和性的n-芳基磺酰-3-取代吲哚及其制备方法和含有其的药物组合物
DK1581538T3 (da) 2002-12-18 2007-06-25 Suven Life Sciences Ltd Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
JP4897221B2 (ja) 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
KR100572325B1 (ko) * 2003-12-17 2006-04-19 삼성전자주식회사 이온 주입 장치 및 이를 이용한 이온 주입 방법
US7777049B2 (en) 2004-01-09 2010-08-17 Ratiopharm Gmbh Crystalline forms of Rizatriptan benzoate
CA2553652A1 (en) * 2004-01-28 2005-08-18 Ratiopharm Gmbh Synthesis methods and intermediates for the manufacture of rizatriptan
WO2006053116A2 (en) * 2004-11-10 2006-05-18 Dr. Reddy's Laboratories Ltd. Rizatriptan process
CA2586612C (en) 2004-11-18 2016-10-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
ES2270717B1 (es) * 2005-08-08 2008-03-01 Ragactives, S.L. Procedimiento para la obtencion de derivados de triptamina.
JP2009504575A (ja) * 2005-08-11 2009-02-05 メルク フロスト カナダ リミテツド 新規の置換された１，２，３，−トリアゾリルメチル−ベンゾチオフェン又は−インドール並びにロイコトリエン生合成阻害剤としてのそれらの使用
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20090062550A1 (en) * 2005-11-14 2009-03-05 Matrix Laboratories Ltd Process for the Large Scale Production of Rizatriptan Benzoate
EP1981860B1 (en) 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2032545A2 (en) * 2006-05-25 2009-03-11 Synta Pharmaceuticals Corporation Compounds that modulate hsp90 activity and methods for identifying same
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009049030A1 (en) * 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20090294028A1 (en) * 2008-06-03 2009-12-03 Nanochip, Inc. Process for fabricating high density storage device with high-temperature media
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011041635A2 (en) * 2009-10-02 2011-04-07 Cardiofocus, Inc. Cardiac ablation system with inflatable member having multiple inflation settings
SI2533640T1 (sl) * 2010-02-08 2017-02-28 Medivation Technologies, Inc. Postopki sinteze derivatov dihidropiridoftalazinona
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013120045A1 (en) * 2012-02-10 2013-08-15 University Of Utah Research Foundation Substituted 1h-indazol-1-ol analogs as inhibitors of beta catenin/tcf protein-protein interactions
CN103739594A (zh) * 2012-10-17 2014-04-23 南京大学 一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
PT3300500T (pt) 2015-05-20 2020-05-19 Amgen Inc Agonistas triazóis do receptor apj
US20170119738A1 (en) * 2015-10-28 2017-05-04 Dr. Reddy's Laboratories, Ltd. Pharmaceutical compositions for rizatriptan
CA3010568C (en) 2016-01-27 2023-10-17 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017189893A1 (en) 2016-04-27 2017-11-02 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475437A (en) * 1964-06-05 1969-10-28 Boehringer Sohn Ingelheim 3-tertiary amino lower alkylpseudoindoles
GB1237008A (en) * 1968-12-18 1971-06-30 Pfizer Ltd Novel indoline derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
DE2520816C3 (de) * 1975-05-09 1979-02-15 Bayer Ag, 5090 Leverkusen Methinfarbstoffe
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
NZ197998A (en) * 1980-08-12 1985-08-16 Glaxo Group Ltd 5-amino(methyl)-1h-indol-3-ylalkaneamines
IT1171449B (it) * 1980-08-12 1987-06-10 Glaxo Group Ltd Composti eterociclici indolici procedimento per produrli e composizioni farmaceutiche che li contengono
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4453001A (en) * 1982-02-22 1984-06-05 Sandoz, Inc. Isoxazolyl indolamines as intermediates
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
US4692531A (en) * 1984-06-22 1987-09-08 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
US4663526A (en) * 1984-12-26 1987-05-05 Emil Kamieniecki Nondestructive readout of a latent electrostatic image formed on an insulating material
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
GB8527619D0 (en) * 1985-11-08 1985-12-11 Glaxo Group Ltd Chemical compounds
US4881967A (en) * 1986-12-10 1989-11-21 E. I. Du Pont De Nemours And Company Heterocyclic 2,3-dihydrobenzofuran herbicides
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
HU219974B (hu) * 1990-06-07 2001-10-28 Astrazeneca Ab, Heterociklusos csoporttal helyettesített indolszármazék, előállítása és a vegyületet hatóanyagként tartalmazó gyógyszerkészítmények
AU2363492A (en) * 1991-08-03 1993-03-02 Smithkline Beecham Plc 5-ht4 receptor antagonists
KR930011238A (ko) * 1991-11-12 1993-06-24 오리 노리오 스태틱 알에이엠(ram)의 메모리셀 및 그 메모리셀어레이
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents

Also Published As

Publication number Publication date
GR3025026T3 (en) 1998-01-30
NO180447C (no) 1997-04-23
SG50409A1 (en) 1998-07-20
CN1038681C (zh) 1998-06-10
EP0497512A2 (en) 1992-08-05
CA2238140A1 (en) 1992-08-02
SI9210101B (en) 2001-06-30
SA94140534B1 (ar) 2006-05-15
ES2162188T3 (es) 2001-12-16
CN1064485A (zh) 1992-09-16
JPH05140151A (ja) 1993-06-08
YU48236B (sh) 1997-08-22
CA2060139A1 (en) 1992-08-02
NO1999005I1 (no) 1999-04-09
HU211516A9 (en) 1995-11-28
CN1161834A (zh) 1997-10-15
IL100756A (en) 1996-01-19
LU90338I2 (fr) 1999-03-15
CN1157821A (zh) 1997-08-27
SI9210101A (en) 1996-08-31
ATE158582T1 (de) 1997-10-15
HUT61013A (en) 1992-11-30
CZ283018B6 (cs) 1997-12-17
EP0778275A1 (en) 1997-06-11
LV12090A (lv) 1998-07-20
DE19975007I2 (de) 2004-08-12
CY2095B1 (en) 2002-04-05
DE69222329D1 (de) 1997-10-30
CA2238140C (en) 2002-06-18
NL980019I1 (nl) 1998-08-03
CN1060479C (zh) 2001-01-10
HRP930777A2 (en) 1997-10-31
EP0778275B1 (en) 2001-10-10
ES2106822T3 (es) 1997-11-16
GR3036864T3 (en) 2002-01-31
AU644939B2 (en) 1993-12-23
NO920424L (no) 1992-08-03
MX9200405A (es) 1992-08-01
SK278998B6 (sk) 1998-05-06
BG62024B2 (bg) 1998-12-30
EP0497512A3 (en) 1992-12-16
NO180447B (no) 1997-01-13
EP0497512B1 (en) 1997-09-24
JP2500280B2 (ja) 1996-05-29
NO920424D0 (no) 1992-01-31
IL100756A0 (en) 1992-09-06
FI107154B (fi) 2001-06-15
DE69222329T2 (de) 1998-04-09
US5298520A (en) 1994-03-29
HU222350B1 (hu) 2003-06-28
HRP930777B1 (en) 2001-04-30
CN1128617C (zh) 2003-11-26
CN1161967A (zh) 1997-10-15
CA2060139C (en) 1998-12-01
US5602163A (en) 1997-02-11
CN1061654C (zh) 2001-02-07
AU1068092A (en) 1992-08-06
IE920342A1 (en) 1992-08-12
HU9200299D0 (en) 1992-04-28
FI920442A0 (fi) 1992-01-31
FI920442L (fi) 1992-08-02
US5602162A (en) 1997-02-11
DK0497512T3 (da) 1997-10-27
LV12090B (en) 1998-09-20
US5451588A (en) 1995-09-19
KR920016444A (ko) 1992-09-24
KR100212111B1 (ko) 1999-08-02
CS19892A3 (en) 1992-08-12
NZ241394A (en) 1994-04-27

Similar Documents

Publication Publication Date Title
YU10192A (sh) Postupak za dobijanje derivata imidazola, triazola i tetrazola
DE60017582D1 (de) Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen
KR920701167A (ko) 약제학적 활성 화합물
EE200200079A (et) Heteropolütsüklilised ühendid ja nende kasutaminemetabotroopsete glutamaadiretseptorite antagonistidena
NO160439C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-derivater.
CA2060624A1 (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
KR950701317A (ko) 인돌 유도체(Indole Derivative)
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
ATE92478T1 (de) Substituierte pyrrol-, pyrazol- und triazolangiotensin ii-antagonisten.
YU173791A (sh) Indol i benzimidazol-supstituisani imidazol i benzimidazol derivati
DE3684431D1 (de) Derivate des ((4-(4-(4-phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2yl)methyl)-1h-imidazol und 1h-1,2,4-triazol.
KR960704852A (ko) 아졸 유도체 및 이의 약제학적 조성물 (Azole derivative and pharmaceutical composition thereof)
YU48826B (sh) Derivati benzimidazola i postupak njihovog dobijanja
ATE119160T1 (de) Heterozyklische derivate, ihre herstellung und ihre anwendung in der therapie als paf- antagoniste.
MA22540A1 (fr) Diaminophtalimides substitues et derives analogues .
DE69109090D1 (de) 2-substituierte 4,5-diphenylimidazole.
RU93058417A (ru) Производные пиридон-карбоновой кислоты, антимикробный агент
YU7302A (sh) Heterociklična jedinjenja za inhibiranje angiogeneze
ATE187448T1 (de) Morpholinderivate
RS50033B (sr) Derivati etansulfonil-piperidina
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
NO833529L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alfa-aryl-alfa-pyridylalkansyrederivater
SE7713574L (sv) Imidazolderivat
ES8503946A1 (es) Agentes antimicoticos con elevada liberacion del producto activo